Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2023 | Predictors of conversion from positive to negative MOG antibody status

Michael Levy, MD, PhD, Massachusetts General Hospital and Harvard Medical School, Boston, MA, discusses a recent study investigating predictors of conversion from positive to negative myelin oligodendrocyte glycoprotein (MOG) antibody status. The study investigated cases over two years and found that if you converted from seropositive to seronegative, the risk of relapse is lower. Therefore, looking forward, this shows that it is meaningful to check the patient’s MOG antibody status and level every six months to witness the trend. Overall, the data suggests that being seronegative has a predictor value of a lower risk of relapse. This interview took place at the AAN Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Dr Levy receives consulting fees from Alexion, which is the manufacturer of ravulizumab, as well as other companies that make medications for NMOSD including Horizon (Amgen), and Genentech (Roche).